(NYSE: ANVS) Annovis Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.65%.
Annovis Bio's earnings in 2025 is -$24,884,444.On average, 6 Wall Street analysts forecast ANVS's earnings for 2025 to be -$36,224,149, with the lowest ANVS earnings forecast at -$36,621,692, and the highest ANVS earnings forecast at -$35,898,163. On average, 6 Wall Street analysts forecast ANVS's earnings for 2026 to be -$37,777,218, with the lowest ANVS earnings forecast at -$39,218,975, and the highest ANVS earnings forecast at -$31,723,958.
In 2027, ANVS is forecast to generate -$33,791,183 in earnings, with the lowest earnings forecast at -$35,842,507 and the highest earnings forecast at -$31,167,397.